<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808494</url>
  </required_header>
  <id_info>
    <org_study_id>RGH-014</org_study_id>
    <nct_id>NCT02808494</nct_id>
  </id_info>
  <brief_title>Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers</brief_title>
  <official_title>Prospective Collection of Whole Blood Specimens of Subjects Diagnosed With Preeclampsia With Severe Features and/or Fetal Growth Restriction in Support of a Molecular Assay Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Illumina, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sample Collection Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a limited prospective collection of whole blood samples from pregnant women with a
      diagnosis of preterm preeclampsia and/or fetal growth restriction in addition to samples from
      a control group to aid in the development of a Next Generation Sequencing (NGS)-based assay
      to detect molecular markers associated with preterm preeclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cfRNA markers associated with preterm preeclampsia</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Affected Group</arm_group_label>
    <description>Women with a diagnosis of preeclampsia or fetal growth restriction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Unaffected Group</arm_group_label>
    <description>Women who do not have a diagnosis of preeclampsia or fetal growth restriction.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stored for future assay development use.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Affected Group: Pregnant women diagnosed with preterm preeclampsia or fetal growth
        restriction

        Control group: Pregnant women matched for gestational age to the Affected group above
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women 18 years of age or older at enrollment

          2. Pregnant women with a viable singleton gestation

          3. Able to provide written, informed consent

          4. Able to provide 20 mL of whole blood

          5. Diagnosis of preeclampsia with severe features and/or diagnosis of fetal growth
             restriction.

               1. Preeclampsia with severe features is defined as:

                  Proteinuria: Execretion of ≥300mg/24hr (24 hour collection) of protein or a timed
                  excretion that is extrapolated to the 24 hour urine value or a protein/creatinine
                  [both in mg/dL] ratio of at least 0.3 or a qualitative determination of (urine
                  dipstick) of ≥1+ WITH Systolic BP ≥160mmHg or diastolic BP ≥110mmHg on at least 2
                  occasions 4 hours apart while on bedrest but before the onset of labor OR
                  Systolic BP ≥160mmHg or diastolic BP ≥110mmHg on 1 occasion but before the onset
                  of labor, if antihypertensive therapy is initiated due to severe hypertension OR
                  New onset hypertension defined as: Systolic BP ≥140 mmHg or diastolic ≥90 mmHg
                  with one or more of the following features: Thrombocytopenia (&lt;100,000 plts/mL);
                  impaired liver function (AST/ALT 2X ULN); newly developed renal insufficiency
                  (serum creatinine &gt;1.1mg/dL or a doubling of serum creatinine in the absence of
                  other renal disease); pulmonary edema; new onset cerebral disturbances or
                  scotomata

               2. Fetal Growth Restriction defined as:

             Estimated fetal weight by ultrasound at ≥ 19 0/7 weeks gestational age &lt; 5%ile or
             5-10%ile with abnormal umbilical artery Doppler examination (S/D ratio &gt;95%ile for
             gestational age, absent end diastolic flow or reverse end diastolic flow)

          6. Gestational age between 20 0/7 and 33 6/7 weeks determined by ultrasound and/or LMP
             per ACOG guidelines1. A subject diagnosed with preeclampsia without severe features
             prior to 33 6/7 weeks gestation and who is managed expectantly and develops severe
             features after 34 weeks may be included.

        Exclusion Criteria:

          1. Known malignancy

          2. History of maternal organ or bone marrow transplant

          3. Maternal blood transfusion in the last 8 weeks

          4. Chronic hypertension diagnosed prior to current pregnancy

          5. Type I, II or gestational diabetes

          6. Fetal anomaly or known chromosome abnormality

          7. Active labor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Mueller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Illumina, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin O'Shea</last_name>
    <phone>6502042231</phone>
    <email>koshea@illumina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Kitto</last_name>
      <phone>302-733-2379</phone>
      <email>ckitto@christianacare.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelly Ruhstaller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidya Iyer, MBBS</last_name>
      <phone>617-636-0186</phone>
    </contact>
    <investigator>
      <last_name>Errol Norwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Vitale</last_name>
      <phone>732-339-7602</phone>
      <email>tvitale@saintpetersuh.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Ranzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shama Khan</last_name>
      <phone>732-235-6630</phone>
      <email>khansp@rwjms.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Duzyj-Buniak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Materna-Fetal Medicine Specialists</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Obermeier</last_name>
      <phone>856-291-8875</phone>
      <email>eobermeier@virtua.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Librizzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosalyn Chan</last_name>
      <phone>718-670-1707</phone>
      <email>roc9166@nyp.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Skupski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Torres</last_name>
      <phone>212-305-2158</phone>
      <email>ct2179@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>3479310318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Wapner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital Clinical Trials Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Byrnes</last_name>
      <phone>510-663-9582</phone>
      <email>kbyrnes@winthrop.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jolene Muscat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheryl Tocci</last_name>
      <phone>215-762-8582</phone>
      <email>ctocci@drexelmed.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie J Lynch</last_name>
      <phone>347-931-0318</phone>
      <email>sl2739@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lauren Plante</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar</last_name>
    </contact>
    <investigator>
      <last_name>George Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Fetal Growth Restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

